Edgewise Therapeutics (EWTX) EBITDA (2020 - 2026)

Edgewise Therapeutics has reported EBITDA for 7 years, with the latest figure at -$54.1 million in Q1 2026.

• Quarterly EBITDA fell 17.75% year-over-year to -$54.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$199.6 million (down 17.36% YoY) and the FY2025 annual result came in at -$191.4 million, down 20.51% from the prior year.
• EBITDA rose to -$54.1 million in Q1 2026 per EWTX's latest filing, from -$56.0 million in the prior quarter.
• Over five years, EBITDA peaked at -$14.8 million in Q1 2022 and troughed at -$56.0 million in Q4 2025.
• A 5-year average of -$34.7 million and a median of -$34.8 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2025: EBITDA sank 116.22% in 2022, then decreased 11.82% in 2025.
• Over 5 years, EBITDA stood at -$22.1 million in 2022, then tumbled by 53.37% to -$33.9 million in 2023, then plunged by 34.49% to -$45.5 million in 2024, then slipped by 22.92% to -$56.0 million in 2025, then advanced by 3.33% to -$54.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$54.1 million, -$56.0 million, and -$46.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.